Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sanofi licenses US rights to Pozen's cardiovascular disease prevention candidates; rights returned

Executive Summary

Pozen Inc. (develops aspirin-based therapies for out-licensing) has granted Sanofi US exclusive rights to sell its PA8140 and PA32540, two tablets that each contain enteric-coated aspirin and the proton pump inhibitor omeprazole for the prevention of secondary cardiovascular diseases including coronary artery disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register